Stuart BSc - Vertex Pharmaceuticals Ex COO
| VX1 Stock | EUR 441.80 3.80 0.87% |
Insider
Stuart BSc is Ex COO of Vertex Pharmaceuticals Incorporated
| Age | 57 |
| Phone | 617 341 6100 |
| Web | https://www.vrtx.com |
Vertex Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of 0.1733 % which means that it generated a profit of $0.1733 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2767 %, meaning that it generated $0.2767 on every $100 dollars invested by stockholders. Vertex Pharmaceuticals' management efficiency ratios could be used to measure how well Vertex Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Caroline Schlienkamp | Talanx AG | 49 | |
| Erik Fallstrom | SIVERS SEMICONDUCTORS AB | 56 | |
| Mike Taylor | Identiv | N/A | |
| James Kang | Origin Agritech | 54 | |
| Robert Smith | NMI Holdings | 53 | |
| Norman Fitzgerald | NMI Holdings | 56 | |
| Torsten Leue | Talanx AG | 57 | |
| Steven Humphreys | Identiv | 62 | |
| Edgar Puls | Talanx AG | 50 | |
| Wilm Langenbach | Talanx AG | 52 | |
| Amir Khoshniyati | Identiv | N/A | |
| Allison Miller | NMI Holdings | N/A | |
| CCLP CMA | Superior Plus Corp | 62 | |
| Harry Kanwar | Superior Plus Corp | N/A | |
| Ravi Mallela | NMI Holdings | 53 | |
| Bjorn Norrbom | SIVERS SEMICONDUCTORS AB | 72 | |
| Erik Wiklund | SIVERS SEMICONDUCTORS AB | 49 | |
| Yasheng Yang | Origin Agritech | 51 | |
| Geoffery Merszei | Origin Agritech | 68 | |
| Fei Wang | Origin Agritech | 40 | |
| Gengchen Han | Origin Agritech | 58 | |
Management Performance
| Return On Equity | 0.28 | |||
| Return On Asset | 0.17 |
Vertex Pharmaceuticals Leadership Team
Elected by the shareholders, the Vertex Pharmaceuticals' board of directors comprises two types of representatives: Vertex Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Vertex. The board's role is to monitor Vertex Pharmaceuticals' management team and ensure that shareholders' interests are well served. Vertex Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Vertex Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jeffrey MD, Ex Chairman | ||
| Ourania Tatsis, Ex Officer | ||
| MD FASN, Pres CEO | ||
| Susie Lisa, VP Relations | ||
| Stuart BSc, Ex COO | ||
| Mike Tirozzi, SVP Officer | ||
| Damian Esq, Chief VP | ||
| Charles Wagner, Ex CFO | ||
| Kristen Ambrose, Tax, Accounting |
Vertex Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Vertex Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.28 | |||
| Return On Asset | 0.17 | |||
| Profit Margin | 0.37 % | |||
| Operating Margin | 0.49 % | |||
| Current Valuation | 67.44 B | |||
| Shares Outstanding | 257.09 M | |||
| Shares Owned By Insiders | 0.21 % | |||
| Shares Owned By Institutions | 96.26 % | |||
| Price To Earning | 18.50 X | |||
| Price To Book | 6.23 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Vertex Stock
Vertex Pharmaceuticals financial ratios help investors to determine whether Vertex Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Vertex with respect to the benefits of owning Vertex Pharmaceuticals security.